

AMENDMENTS TO THE SPECIFICATION

Kindly insert the enclosed sequence listing into the application between the last page of the specification (page 25) and the first page of the claims (page 26).

Please also amend the specification as shown:

Please amend the paragraph on page 2, lines 3-13, as follows:

A specific site in the N-terminal amino acid sequences of these PARs is cleaved by thrombin or such proteases. Peptide fragments generated by the cleavage bind to the binding site of receptors thereof or themselves to activate the receptors. The amino acid sequences activating the PARs are summarized and expressed according to the one character amino acid expression as below.

PAR-1: SFLLRN-NH₂ (human) **(SEQ ID NO: 1)**

PAR-2: SLIGKV-NH₂ (human) **(SEQ ID NO: 2)**

SLIGRL-NH₂ (mouse) **(SEQ ID NO: 3)**

PAR-3: None

PAR-4: GYPGQV (human) **(SEQ ID NO: 4)**

GYPGKF (mouse) **(SEQ ID NO: 5)**

Please amend the paragraph on page 3, lines 7-12, as follows:

Furthermore, some PAR-2-activating agents have been reported, which have higher activity than the activity of a partial PAR-2 amino acid sequence (SLIGKV) **(SEQ ID NO: 2)** activating human PAR-2 and include trans-cinnamoyl-LIGRL-0-NH₂ **(SEQ ID**

NO: 6 found by Hollenberg et al. (Br. J. Pharmacol. 1998,123, 1434-1440) (PNAS, 95, 7766-7771 (1998); BJP, 125,1445-1454 (1998)).

Please amend the paragraph on page 4, lines 4-12, as follows:

In such circumstances, the present inventors have made intensive investigations. Consequently, the inventors have found that a peptide derivative represented by the general formula (I) has a higher activity than the activity of the partial PAR-2 amino acid sequence (SLIGKV) (**SEQ ID NO: 2**) activating human PAR-2 and is useful as a pharmaceutical agent for the prophylaxis and therapeutic treatment of the decrease of lacrimal fluid secretion, the decrease of saliva secretion or gastrointestinal diseases. Thus, the invention has been achieved.

Please amend the paragraph on page 9, line 23 to page 19, line 1, as follows:

SLIGKV-OH (**SEQ ID NO: 2**) as a known PAR-2 activation peptide was used as a comparative compound, and the results are shown below in Table 1.

Please amend line 11 on page 16, as follows:

Example 1 (**SEQ ID NO: 7**) (Preparation for

Please amend the paragraph on page 18, lines 6-8, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 4-phenethylbenzoic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 18, lines 14-16, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 3-phenylpropionic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 19, lines 3-5, as follows:

The title **(SEQ ID NO: 7)** compound was prepared in the same manner as in Example 1 except that 2,4-dinitrobenzoic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 19, lines 11-13, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 4-methylbenzoic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 19, line 19 to page 20, line 1, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 2-furancarboxylic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 20, lines 7-9, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 2- (4-methoxyphenyl) acetic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 20, lines 15-17, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 2-naphthalenecarboxylic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 21, lines 3-5, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 2,4, 5-trifluorobenzoic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 21, lines 11-13, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 4-pyridinecarboxylic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 21, line 19 to page 22, line 2, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 2- (3-thienyl) acetic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 22, lines 8-10, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 2-thiophenecarboxylic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 22, lines 16-18, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 4-phenylbenzoic acid was used instead of 4-methoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 23, lines 4-6, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 6-quinolinecarboxylic acid was used instead of 4-metoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 23, lines 12-14, as follows:

The title compound **(SEQ ID NO: 7)** was prepared in the same manner as in Example 1 except that 3-quinolinecarboxylic acid was used instead of 4-metoxybenzoic acid as the acid to be coupled.

Please amend the paragraph on page 24, lines 11-14, as follows:

The title compound **(SEQ ID NO: 6)** was prepared in the same manner as in Example 16 except that Arginine and Leucine was used respectively instead of Lysine and Valine as the amino acid to be coupled.

Please amend the paragraph on page 25, lines 3-6, as follows:

The title compound **(SEQ ID NO: 6)** was prepared in the same manner as in Example 6 except that Arginine and Leucine was used respectively instead of Lysine and Valine as the amino acid to be coupled.